Diabetic Retinopathy in Pregnancy: A Population-Based Study of Women with Pregestational Diabetes

Aoife M. Egan, Lyle McVicker, Adrienne Heerey, Louise Carmody, Fiona Harney, and Fidelma P. Dunne

1Galway Diabetes Research Centre, National University of Ireland Galway and University Hospital Galway, Newcastle, Galway, Ireland
2Department of Ophthalmology, National University of Ireland Galway and University Hospital Galway, Newcastle, Galway, Ireland

Correspondence should be addressed to Aoife M. Egan; aoiﬂe.egan@gmail.com

Received 17 February 2015; Revised 25 March 2015; Accepted 26 March 2015

The aim of this observational study was to evaluate screening and progression of diabetic retinopathy during pregnancy in women with pregestational diabetes attending five antenatal centres along the Irish Atlantic seaboard. An adequate frequency of screening was defined as at least two retinal evaluations in separate trimesters. Progression was defined as at least one stage of deterioration of diabetic retinopathy and/or development of diabetic macular edema on at least one eye. Women with pregestational diabetes who delivered after 22 gestational weeks (n = 307) were included. In total, 185 (60.3%) had an adequate number of retinal examinations. Attendance at prepregnancy care was associated with receiving adequate screening (odds ratio 6.23; CI 3.39–11.46 (P < 0.001)). Among those who received adequate evaluations (n = 185), 48 (25.9%) had retinopathy progression. Increasing booking systolic blood pressure (OR 1.03, CI 1.01–1.06, P = 0.02) and greater drop in HbA1c between first and third trimesters of pregnancy (OR 2.05, CI 1.09–3.87, P = 0.03) significantly increased the odds of progression. A significant proportion of women continue to demonstrate retinopathy progression during pregnancy. This study highlights the role of prepregnancy care and the importance of close monitoring during pregnancy and identiﬁes those patients at the highest risk for retinopathy progression.

1. Introduction

Deterioration of diabetic retinopathy during pregnancy is well described in women with pregestational diabetes mellitus [1–3]. This progression is inﬂuenced by multiple factors including the pregnancy itself, glycemic control before and during pregnancy, and the presence of preexisting retinopathy [4, 5]. Maternal medical complications including pregnancy-induced hypertension, diabetic nephropathy, and preeclampsia are also associated with progression of retinopathy [6, 7]. Unfortunately, study sample size has frequently limited the evaluation of additional risk factors and many studies predate the era of modern diabetes care in pregnancy which includes tight glycemic control and blood pressure management [1, 2, 8, 9]. Additionally, there is no data on screening rates within populations or on factors associated with receiving adequate retinal examinations during pregnancy.

The Atlantic Diabetes in Pregnancy (Atlantic DIP) initiative was established in 2005 and represents ﬁve antenatal centers along the Irish Atlantic seaboard, covering a population of 500,000 mixed urban and rural dwellers. The group offers women specialist-led, evidence-based care before, during, and after pregnancy and has signiﬁcantly improved local outcomes in women with diabetes in pregnancy [10].

The aim of this study was to review the frequency of retinal examination during pregnancy in the Atlantic DIP cohort and examine maternal factors associated with receiving the optimal number of examinations. Additionally, we documented the progression of diabetic retinopathy during pregnancy and factors associated with this progression.

2. Methods

2.1. Study Design and Population. This study was designed as an observational study of retinopathy status during
pregnancy in women with pregestational diabetes. Research ethics committee approval was obtained and women were recruited between September 2006 and December 2012. Women with singleton pregnancies who provided informed consent were included. As per previous studies, women were classified as having pregestational diabetes on the following basis: (1) an established diagnosis of type one or type two diabetes mellitus prior to conception or (2) glycosylated hemoglobin (HbA1c) greater than 6.5% in the first trimester [11]. Data were collected from study entry until 12 weeks postpartum using an optimized digital database, namely, DIAMOND (Hicom).

2.2. Procedures. Prior to pregnancy, during annual review appointments, all women were advised regarding the need to plan pregnancy and were offered the opportunity to attend a dedicated, prepregnancy service. During pregnancy, each woman received standard advice on diet and exercise along with a dietician review. Education was provided on self-directed glucose monitoring and each woman was advised on glycemic targets. Women were reviewed on a fortnightly basis and telephoned on a weekly basis. Insulin was introduced (in the setting of type two diabetes mellitus) or adjusted if home glucose readings were outside the following ranges on more than three consecutive days: fasting glucose 5.0 mmol/L or a 2-hour postprandial reading of 7.0 mmol/L. Oral hypoglycemic agents were not used during the study period. Retinal screening should occur at least twice during pregnancy in separate trimesters and if established retinopathy is present, then retinal examination should take place more frequently. For the purposes of this study, we accepted at least two retinal evaluations in separate trimesters as adequate. During the study period, retinal examination took place in the locality of each antenatal center and results were forwarded to the respective center. At each visit, visual acuity was measured bilaterally using the Snellen chart. The pupils were then dilated with tropicamide 1% and ophthalmological examinations were performed using a two-field photography system. These images were reviewed by an accredited retinal grader. If photo screening was not performed or if the images were abnormal, an experienced ophthalmologist performed an eye examination. Progression was defined as at least one stage of deterioration of diabetic retinopathy and/or development of diabetic macular edema on at least one eye. Grading standards as outlined by the National Screening Committee in the United Kingdom were followed (Table 1) [12]. Antihypertensive therapy was initiated when blood pressure was ≥ 135/85 mmHg. Labetalol was the first-choice antihypertensive agent, followed by methyldopa when needed.

2.3. Statistical Analysis. Data were analyzed using Statistical Package for the Social Sciences (SPSS) version 20.0 (IBM). Hypothesis testing was performed on the data of equal variance and normal distribution using an unpaired Student’s t-test. The Mann-Whitney U test was used as the equivalent nonparametric test. Chi squared analysis was used to compare sample proportions. Binary logistic regression was utilized to assess the association of multiple covariates with receipt of adequate retinal evaluations and the progression of retinopathy. Data are expressed as means ± standard deviation (SD) or the mean, adjusted odds ratios (aORs), and 95% confidence intervals (CI). Statistical significance was accepted when the 95% CI did not contain one (regression analyses/ratios) or zero (multiple group comparisons/means). The significance level (α) was accepted when <0.05 for two-tailed analyses.

3. Results
We identified 307 women with pregestational diabetes who delivered after 22 gestational weeks from the Atlantic DIP database. This cohort comprised 208 (67.8%) with type one diabetes and 99 (32.2%) with type two diabetes. The majority
Table 2: Characteristics of women who received an adequate number of retinal examinations versus those who did not (n = 307).

|                                      | Adequate number of retinal examinations | Inadequate number of retinal examinations | P value |
|--------------------------------------|----------------------------------------|------------------------------------------|---------|
| N (%)                                | 185 (60.3%)                            | 122 (39.7%)                              |         |
| Type 1 diabetes                      | 134 (72.4%)                            | 74 (60.7%)                               |         |
| Type 2 diabetes                      | 51 (27.6%)                             | 48 (39.3%)                               |         |
| Age (years)                          | 32.9 ± 5.3                             | 31.5 ± 5.4                               | 0.02    |
| Gravida                              | 2.4 ± 1.5                              | 2.8 ± 2.2                                | 0.16    |
| Parity                               | 0.9 ± 1.1                              | 1.0 ± 1.3                                | 0.13    |
| Caucasian                            | 174 (94.1%)                            | 104 (85.2%)                              | 0.01    |
| Diabetes duration (years)            | 11.28 ± 5.68                           | 9.25 ± 5.77                              | 0.007   |
| Nonsmokers                           | 158 (85.4%)                            | 110 (90.2%)                              | 0.29    |
| Attendance at prepregnancy care      | 108 (58.4%)                            | 21 (17.2%)                               | <0.001  |
| Folic acid                           | 129 (69.7%)                            | 66 (54.1%)                               | 0.001   |
| 1st trimester HbA1c % (mmol/mol)     | 7.20 ± 1.48 (55.0 ± 4.5)               | 7.06 ± 1.63 (54.0 ± 4.6)                 | 0.47    |
| 3rd trimester HbA1c % (mmol/mol)     | 6.28 ± 0.88 (45.0 ± 2.6)               | 6.37 ± 0.96 (46.0 ± 2.9)                 | 0.43    |
| Years 2006–2008                       | 48 (25.9%)                             | 84 (68.9%)                               |         |
| Years 2009–2012                       | 137 (74.1%)                            | 38 (31.1%)                               |         |

Data expressed as mean ± standard deviation (SD), number of patients, and % of group.

Table 3: Maternal factors associated with receiving appropriate retinal evaluation during pregnancy.

|                                      | Odds ratio | Confidence interval | P value |
|--------------------------------------|------------|---------------------|---------|
| Age                                  | 1.02       | 0.97–1.08           | 0.38    |
| Ethnicity                            | 0.71       | 0.27–1.85           | 0.48    |
| Diabetes type                        | 0.95       | 0.46–1.98           | 0.89    |
| Diabetes duration                    | 1.03       | 0.99–1.07           | 0.15    |
| Attendance at prepregnancy care      | 6.23       | 3.39–11.46          | <0.001  |
| Folic acid use                       | 0.97       | 0.56–1.67           | 0.97    |

Logistic regression analysis revealed that increasing systolic blood pressure at booking (OR 1.03, CI 1.01–1.06,
Table 4: Women who received appropriate screening (n = 185). Characteristics of those who demonstrated retinopathy progression compared with those who did not.

| Characteristic                              | No progression | Progression | P value |
|--------------------------------------------|----------------|-------------|---------|
| N (%)                                      | 137 (74.1%)    | 48 (25.9%)  |         |
| Diabetes type 1                            | 92 (67.2%)     | 42 (87.5%)  |         |
| Diabetes type 2                            | 45 (32.8%)     | 6 (12.5%)   |         |
| Age (years)                                | 32.64 ± 5.35   | 33.60 ± 5.15| 0.28    |
| Caucasian ethnicity                        | 128 (93.4%)    | 46 (95.8%)  | 0.54    |
| Parity                                     | 0.99 ± 1.16    | 0.73 ± 1.05 | 0.09    |
| Gravida                                    | 2.44 ± 1.54    | 2.21 ± 1.53 | 0.17    |
| Body mass index (kg/m²)                    | 28.78 ± 6.32   | 27.50 ± 5.30| 0.35    |
| Prepregnancy care                          | 82 (59.9%)     | 26 (54.2%)  | 0.49    |
| Folic acid                                 | 97 (70.8%)     | 32 (66.7%)  | 0.59    |
| Diabetes duration (years)                  | 9.79 ± 8.36    | 14.43 ± 8.42| <0.001  |
| Excessive weight gain in pregnancy         | 76 (55.5%)     | 29 (60.4%)  | 0.88    |
| 1st trimester HbA1c                        | 703 ± 1.39     | 767 ± 1.62  | 0.01    |
| 3rd trimester HbA1c                        | 6.27 ± 0.93    | 6.29 ± 0.70 | 0.89    |
| HbA1c (%)                                  | 45.0 ± 2.8     | 45.0 ± 2.1  |         |
| Change in HbA1c between 1st and 3rd trimester (%) | 0.74 ± 0.90 (9.6 ± 11.7) | 1.38 ± 1.33 (17.9 ± 17.3) | 0.004 |
| Preeclampsia                               | 17 (12.4%)     | 7 (14.6%)   | 0.80    |
| Systolic blood pressure at booking (mmHg)  | 122.1 ± 13.0   | 128.6 ± 18.0| 0.03    |
| Diastolic blood pressure at booking (mmHg) | 72.89 ± 10.3   | 76.0 ± 9.4  | 0.73    |
| Nonsmoker                                  | 118 (86.1%)    | 40 (83.4%)  | 0.63    |
| Baseline retinal findings                  |                |             |         |
| R0 (no retinopathy)                        | 82 (59.9%)     | 32 (66.7%)  |         |
| R1 (background)                            | 33 (24.1%)     | 9 (18.8%)   |         |
| R2 (preproliferative)                      | 6 (4.4%)       | 4 (8.3%)    |         |
| R3 (proliferative)                         | 10 (7.3%)      | 0 (0%)      |         |
| Maculopathy                                | 6 (4.4%)       | 3 (6.3%)    |         |

Data expressed as mean ± standard deviation (SD), number of patients, and % of group.

Table 5: Factors associated with retinopathy progression.

| Factor                                | Odds ratio | CI          | P value |
|---------------------------------------|------------|-------------|---------|
| Duration of diabetes                  | 1.04       | 0.99–1.10   | 0.12    |
| Diabetes type                         | 0.47       | 0.15–1.54   | 0.21    |
| 1st trimester HbA1c reduction between 1st and 3rd trimester | 0.83       | 0.53–1.30   | 0.42    |
| Systolic blood pressure at booking    | 2.05       | 1.09–3.87   | 0.03    |
| at booking                            | 1.03       | 1.01–1.06   | 0.02    |

P = 0.02) and greater drop in HbA1c between first and third trimesters of pregnancy (OR 2.05, CI 1.09–3.87, P = 0.03) significantly increased the odds of retinopathy progression. Duration of diabetes, diabetes type, and first trimester HbA1c were not associated with increased odds of progression and these results are outlined in Table 5.

Baseline retinal findings are outlined in Table 4. Of those women who developed progression (n = 48), 32 (66.7%) had no retinopathy at baseline. A total of 26 (54.2%) women progressed from no retinopathy to level 1 (background) retinopathy only. A further 7 (14.6%) progressed from level 1 to level 2 (preproliferative) retinopathy and 6 women (12.5%) progressed to level 3 (proliferative) retinopathy and required laser therapy. Two women in the latter group had also received prepregnancy laser therapy. Finally, 6 (12.5%) women developed mild maculopathy and three (6.3%) experienced a worsening of preexisting maculopathy and required laser therapy. Among the group with maculopathy development (n = 9), 4 (44.4%) women received prepregnancy laser therapy.

4. Discussion

In an unselected population of women with pregestational diabetes, we demonstrate that 60.3% had an adequate number of ophthalmological examinations during pregnancy. Attendance at prepregnancy care was strongly associated with receiving adequate retinal evaluation in the subsequent pregnancy. Despite intensive glycemic control and antihypertensive therapy as required, progression of retinopathy was
observed in 14% of the total group and in 26% of those who had more than one retinal examination during pregnancy.

Recommendations for retinopathy screening and management in pregnancy vary significantly. The American Diabetes Association advises an eye examination in the first trimester with close follow-up throughout pregnancy [13]. The National Institute for Health and Clinical Excellence (NICE) in the United Kingdom recommends retinal assessment following the first antenatal clinic appointment and again at 28 weeks if the first assessment is normal. If any diabetic retinopathy is present, an additional retinal assessment should be performed at 16–20 weeks [14]. For the purposes of this study, we accepted a minimum of two retinal evaluations in separate trimesters in accordance with local guidelines. Unfortunately, despite the existence of these guidelines, there was no retinal evaluation in 35% of cases and just one evaluation in a further 9%. While many studies in the area of diabetic retinopathy in pregnancy include selected patients with complete ophthalmological evaluations only [1,15], a study of women with type two diabetes reported that only 73% had the available ophthalmological examinations [2]. In relation to this current study, there is not an automatic recall system for retinal evaluation in our antenatal centers and each woman must be referred individually. It is the opinion of the authors that an automatic, standardized system of follow-up as demonstrated by Hampshire et al. would improve screening and follow-up rates [4]. The majority of women who had just one eye examination were retinopathy-free and the lack of follow-up in later pregnancy may reflect a perceived “minimal risk” on behalf of the patient and health care provider with more focus being placed on those patients with established retinopathy.

Another interesting observation presented herein is the association between attendance at a prepregnancy care program and adequate retinal assessment in the subsequent pregnancy. It is reasonable to assume that the educational component of the program informs women of recommended intervals for ophthalmology review during pregnancy and these women are more likely to ensure they receive and attend appointments. The increased attendance at prepregnancy care undoubtedly explains the higher proportion of women taking prepregnancy folic acid in the group who received adequate eye assessments during pregnancy. Unfortunately, we do not have information regarding the exact timing of prepregnancy care and levels of metabolic control and blood pressure at the time of attendance. Although there was no significant difference in progression of retinopathy between patients attending prepregnancy care and those who did not, improved metabolic control just before pregnancy may have influenced retinopathy progression during the subsequent pregnancy. Finally, the higher rates of adequate screening in the latter four years of the study reflect improvements in clinical care delivery as the Atlantic DIP program became established.

This study highlights the ongoing risk of retinopathy progression during pregnancy particularly among women with type one diabetes. Rasmussen et al. evaluated 80 patients with type two diabetes and observed progression in 14% [2]. Vestgaard et al. evaluated 102 women with type one diabetes and noted progression in 27% [6]. These studies did not find an association between glucose control and progression of retinopathy but this may be due to very tight prepregnancy glycemic control or a type-two error due to a lesser number of included subjects. However, our observations reinforce other published works that noted both significant and nonsignificant trends towards progression of retinopathy in the setting of a greater drop in HbA1c during the pregnancy [5,15,16]. While the third trimester HbA1c was similar between groups that did and did not progress in our study, the first trimester value was on average 0.5% higher in the group that developed retinopathy progression. The importance of prepregnancy glycemic optimization should be highlighted as it is associated with a tendency toward less progression of retinopathy compared with waiting until pregnancy is confirmed in type one diabetes [2, 15]. In the setting of an unplanned pregnancy with poor glycemic control, the authors believe that glycemic control should be prioritized and appropriately optimized as the long-term consequences of poor glycemic control during the pregnancy appear to outweigh those of retinopathy progression [10, 15, 17, 18]. This issue has also received attention in studies involving a more general diabetes population. For example, although early worsening of diabetic retinopathy was noted in a higher proportion of those assigned to intensive treatment in the Diabetes Control and Complications Trial (DCCT), the long-term benefits of intensive insulin treatment greatly outweighed the risks of this early worsening [19]. The association between retinopathy progression and systolic blood pressure at booking is not unexpected as hypertensive disorders of pregnancy and indeed higher systolic blood pressure are factors known to negatively influence retinopathy [7, 20, 21].

In relation to the complication severity, two-thirds of women who experienced retinopathy progression developed background retinopathy only and no women with a normal retinal examination during trimester one developed sight-threatening disease or required laser therapy. All women who developed sight-threatening disease had significant changes identified at baseline. These findings are reassuring, particularly as Hellstedt et al. demonstrated a regression of mild retinopathy postpartum in a cohort of women with type one diabetes [22]. A limitation of the study is that we do not have postpartum evaluations to determine the longer-term progression of retinopathy. However, Arun and Taylor studied women with type one diabetes for 5 years after delivery and concluded that pregnancy is not associated with postpartum worsening of retinopathy [17]. Additionally, in the Pittsburgh EDC pregnancy study, it was observed that the overall prevalence of retinopathy in women with prior pregnancy was similar to that of matched nulliparous women [18].

Overall, this was a robust, nested cohort analysis performed retrospectively with data managed prospectively within the Atlantic DIP database. Although the observational study design has inherent limitations including the potential influence of unmeasured covariates such as additional medications, we have used robust statistical methods to evaluate rates of retinopathy progression and employed regression analysis to demonstrate factors associated with
disease progression and adequate retinal evaluation during pregnancy. The management of the patients included in this study is a reflection of real-life clinical practice and involves patients with both type one and type two diabetes with varying durations of disease. The findings are externally valid particularly in relation to other predominantly Caucasian populations.

5. Conclusions

In summary, with the establishment of a structured antenatal care program, more women are receiving an adequate number of retinal examinations during pregnancy. The introduction of an automatic recall system has the potential to improve service delivery. A significant proportion of women continue to experience deterioration in retinopathy during pregnancy and this validates the need for close follow-up. Finally, the importance of prepregnancy care to fully inform women of the need for more frequent retinal assessments during pregnancy and allow preconceptual optimization of glycemic control and blood pressure should be emphasized. These results will assist the health care professional design and provide high quality antenatal care for women with pregestational diabetes mellitus.

Ethical Approval

Local ethics committee approval was obtained for this study. All procedures followed were in accordance with the Helsinki Declaration of 1975, as revised in 2008.

Disclosure

The Health Research Board of Ireland did not have a role in the study design, execution, or data analysis and it did not have a role in drafting the paper or the decision to submit the paper for publication.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgment

This study was funded by the Health Research Board of Ireland.

References

[1] B. E. K. Klein, S. E. Moss, and R. Klein, “Effect of pregnancy on progression of diabetic retinopathy,” *Diabetes Care*, vol. 13, no. 1, pp. 34–40, 1990.

[2] K. L. Rasmussen, C. S. Laugesen, L. Ringholm, M. Vestgaard, P. Damm, and E. R. Mathiesen, “Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes,” *Diabetologia*, vol. 53, no. 6, pp. 1076–1083, 2010.

[3] Y. Omori, S. Minei, T. Testuo, K. Nemoto, M. Shimizu, and M. Sanaka, “Current status of pregnancy in diabetic women. A comparison of pregnancy in IDDM and NIDDM mothers,” *Diabetes Research and Clinical Practice*, vol. 24, supplement, pp. S273–S278, 1994.

[4] R. Hampshire, H. Wharton, R. Leigh, A. Wright, and P. Dodson, “Screening for diabetic retinopathy in pregnancy using photographic review clinics,” *Diabetic Medicine*, vol. 30, no. 4, pp. 475–477, 2013.

[5] E. Y. Chew, J. L. Mills, B. E. Metzger et al., “Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study,” *Diabetes Care*, vol. 18, no. 5, pp. 631–637, 1995.

[6] M. Vestgaard, L. Ringholm, C. S. Laugesen, K. L. Rasmussen, P. Damm, and E. R. Mathiesen, “Pregnancy-induced sight-threatening diabetic retinopathy in women with Type 1 diabetes,” *Diabetic Medicine*, vol. 27, no. 4, pp. 431–435, 2010.

[7] M. Lövsetam-Adrian, C. Agardh, A. Aberg, and E. Agardh, “Pre-eclampsia is a potent risk factor for deterioration of retinopathy during pregnancy in type 1 diabetic patients,” *Diabetic Medicine*, vol. 14, no. 12, pp. 1059–1065, 1997.

[8] C. M. Dibble, N. K. Kochenour, R. J. Worley, F. H. Tyler, and M. Swartz, “Effect of pregnancy on diabetic retinopathy,” *Obstetrics & Gynecology*, vol. 59, no. 6, pp. 699–704, 1982.

[9] J. H. Price, D. R. Hadden, D. B. Archer, and J. M. G. Harley, “Diabetic retinopathy in pregnancy,” *British Journal of Obstetrics & Gynaecology*, vol. 91, no. 1, pp. 11–17, 1984.

[10] L. A. Owens, G. Avalos, B. Kirwan, L. Carmody, and F. Dunne, “ATLANTIC DIP: closing the loop: a change in clinical practice can improve outcomes for women with pregestational diabetes,” *Diabetes Care*, vol. 35, no. 8, pp. 1669–1671, 2012.

[11] A. M. Egan, M. C. Dennedy, W. Al-Ramli, A. Heerey, G. Avalos, and F. Dunne, “ATLANTIC-DIP: excessive gestational weight gain and pregnancy outcomes in women with gestational or pregestational diabetes mellitus,” *Journal of Clinical Endocrinology and Metabolism*, vol. 99, no. 1, pp. 212–219, 2014.

[12] UK National Screening Committee, *Essential Elements in Developing a Diabetic Retinopathy Screening Programme*, National Screening Programme for Diabetic Retinopathy Workbook 4.3, 2009.

[13] American Diabetes Association, “Standards of medical care in diabetes—2013,” *Diabetes Care*, vol. 36, supplement 1, pp. S11–S66, 2013.

[14] NICE guidelines [CG63], Diabetes in pregnancy: management of diabetes and its complications from pre-conception to the postnatal period, 2008, http://www.nice.org.uk/guidance/cg63/chapter/guidance.

[15] The Diabetes Control and Complications Trial Research Group, “Effect of pregnancy on microvascular complications in the diabetes control and complications trial,” *Diabetes Care*, vol. 23, no. 8, pp. 1084–1091, 2000.

[16] R. C. Temple, V. A. Aldridge, M. J. Sampson, R. H. Greenwood, P. J. Heyburn, and A. Glenn, “Impact of pregnancy on the progression of diabetic retinopathy in Type 1 diabetes,” *Diabetic Medicine*, vol. 18, no. 7, pp. 573–577, 2001.

[17] C. S. Arun and R. Taylor, “Influence of pregnancy on long-term progression of retinopathy in patients with type 1 diabetes,” *Diabetologia*, vol. 51, no. 6, pp. 1041–1045, 2008.

[18] A. Hemachandra, D. Ellis, C. E. Lloyd, and T. J. Orchard, “The influence of pregnancy on IDDM complications,” *Diabetes Care*, vol. 18, no. 7, pp. 950–954, 1995.
[19] The Diabetes Control and Complications Trial Research Group, “Early worsening of diabetic retinopathy in the diabetes control and complications trial,” *Archives of Ophthalmology*, vol. 116, no. 7, pp. 874–886, 1998.

[20] B. Rosenn, M. Miodovnik, G. Krancias et al., “Progression of diabetic retinopathy in pregnancy: association with hypertension in pregnancy,” *American Journal of Obstetrics & Gynecology*, vol. 166, no. 4, pp. 1214–1218, 1992.

[21] R. Axer-Siegel, M. Hod, S. Fink-Cohen et al., “Diabetic retinopathy during pregnancy,” *Ophthalmology*, vol. 103, no. 11, pp. 1815–1819, 1996.

[22] T. Hellstedt, R. Kaaja, K. Teramo, and I. Immonen, “The effect of pregnancy on mild diabetic retinopathy,” *Graefes Archive for Clinical and Experimental Ophthalmology*, vol. 235, no. 7, pp. 437–441, 1997.